Andrei L Gartel

List of Publications by Year
in descending order

80 papers	10,171 citations	71102 41 h-index	64796 79 g-index
82 all docs	82 docs citations	82 times ranked	18100 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
2	Lost in Transcription: p21 Repression, Mechanisms, and Consequences: Figure 1.. Cancer Research, 2005, 65, 3980-3985.	0.9	731
3	The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Molecular Cancer Therapeutics, 2002, 1, 639-49.	4.1	676
4	Transcriptional Regulation of the p21(WAF1/CIP1)Gene. Experimental Cell Research, 1999, 246, 280-289.	2.6	602
5	Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 4510-4515.	7.1	372
6	p21--Negative Regulator of the Cell Cycle. Experimental Biology and Medicine, 1996, 213, 138-149.	2.4	331
7	ROS inhibitor <i>N</i>-acetyl-<scp>L</scp>-cysteine antagonizes the activity of proteasome inhibitors. Biochemical Journal, 2013, 454, 201-208.	3.7	274
8	Activation of Akt/Protein Kinase B Overcomes a G₂/M Cell Cycle Checkpoint Induced by DNA Damage. Molecular and Cellular Biology, 2002, 22, 7831-7841.	2.3	263
9	Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Experimental Cell Research, 2003, 283, 17-21.	2.6	219
10	Identification of a Chemical Inhibitor of the Oncogenic Transcription Factor Forkhead Box M1. Cancer Research, 2006, 66, 9731-9735.	0.9	210
11	FOX(M1) Newsâ€"It Is Cancer. Molecular Cancer Therapeutics, 2013, 12, 245-254.	4.1	179
12	Thiazole Antibiotics Target FoxM1 and Induce Apoptosis in Human Cancer Cells. PLoS ONE, 2009, 4, e5592.	2.5	173
13	FOXM1 in Cancer: Interactions and Vulnerabilities. Cancer Research, 2017, 77, 3135-3139.	0.9	168
14	FoxM1 Is a General Target for Proteasome Inhibitors. PLoS ONE, 2009, 4, e6593.	2.5	166
15	Targeting FOXM1 in cancer. Biochemical Pharmacology, 2013, 85, 644-652.	4.4	144
16	miRNAs: Little known mediators of oncogenesis. Seminars in Cancer Biology, 2008, 18, 103-110.	9.6	131
17	p21 (WAF1/CIP1) Expression Is Induced in Newly Nondividing Cells in Diverse Epithelia and during Differentiation of the Caco-2 Intestinal Cell Line. Experimental Cell Research, 1996, 227, 171-181.	2.6	124
18	RNA interference in cancer. New Biotechnology, 2006, 23, 17-34.	2.7	116

#	Article	IF	Citations
19	Myc-ARF (Alternate Reading Frame) Interaction Inhibits the Functions of Myc. Journal of Biological Chemistry, 2004, 279, 36698-36707.	3.4	102
20	A novel mode of FoxM1 regulation: Positive auto-regulatory loop. Cell Cycle, 2009, 8, 1966-1967.	2.6	97
21	Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in Sâ€‰phase of the cell cycle. Oncogene, 2004, 23, 4173-4176.	5.9	96
22	p53 negatively regulates expression of FoxM1. Cell Cycle, 2009, 8, 3425-3427.	2.6	81
23	A new target for proteasome inhibitors: FoxM1. Expert Opinion on Investigational Drugs, 2010, 19, 235-242.	4.1	79
24	Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle, 2008, 7, 1851-1855.	2.6	76
25	Suppression of FOXM1 Sensitizes Human Cancer Cells to Cell Death Induced by DNA-Damage. PLoS ONE, 2012, 7, e31761.	2.5	75
26	Sp1 and Sp3 activate p21 (WAF1/CIP1) gene transcription in the Caco-2 colon adenocarcinoma cell line. Oncogene, 2000, 19, 5182-5188.	5.9	72
27	p21^{WAF1/CIP1} and cancer: A shifting paradigm?. BioFactors, 2009, 35, 161-164.	5.4	71
28	Activation and repression of p21WAF1/CIP1 transcription by RB binding proteins. Oncogene, 1998, 17, 3463-3469.	5.9	69
29	Is p21 an oncogene?. Molecular Cancer Therapeutics, 2006, 5, 1385-1386.	4.1	64
30	CDK9 Phosphorylates p53 on Serine Residues 33, 315 and 392. Cell Cycle, 2006, 5, 519-521.	2.6	57
31	FOXM1: a potential therapeutic target in human solid cancers. Expert Opinion on Therapeutic Targets, 2020, 24, 205-217.	3.4	57
32	A New Method for Determining the Status of p53 in Tumor Cell Lines of Different Origin. Oncology Research, 2003, 13, 405-408.	1.5	54
33	A Novel Transcriptional Inhibitor Induces Apoptosis in Tumor Cells and Exhibits Antiangiogenic Activity. Cancer Research, 2006, 66, 3264-3270.	0.9	53
34	FoxM1 inhibitors as potential anticancer drugs. Expert Opinion on Therapeutic Targets, 2008, 12, 663-665.	3.4	52
35	Proteasome Inhibitors Induce p53-Independent Apoptosis in Human Cancer Cells. American Journal of Pathology, 2011, 178, 355-360.	3.8	52
36	A role for E2F1 in Ras activation of p21(WAF1/CIP1) transcription. Oncogene, 2000, 19, 961-964.	5.9	49

#	Article	IF	Citations
37	The Growth-Regulatory Role of p21 (WAF1/CIP1). Progress in Molecular and Subcellular Biology, 1998, 20, 43-71.	1.6	44
38	The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA. Oncotarget, 2011, 2, 1218-1226.	1.8	43
39	Thiostrepton, proteasome inhibitors and FOXM1. Cell Cycle, 2011, 10, 4341-4342.	2.6	42
40	Honokiol is a FOXM1 antagonist. Cell Death and Disease, 2018, 9, 84.	6.3	42
41	Micelle-Encapsulated Thiostrepton as an Effective Nanomedicine for Inhibiting Tumor Growth and for Suppressing FOXM1 in Human Xenografts. Molecular Cancer Therapeutics, 2011, 10, 2287-2297.	4.1	41
42	Nucleophosmin Interacts with FOXM1 and Modulates the Level and Localization of FOXM1 in Human Cancer Cells. Journal of Biological Chemistry, 2011, 286, 41425-41433.	3.4	40
43	Combination of Oxidative Stress and FOXM1 Inhibitors Induces Apoptosis in Cancer Cells and Inhibits Xenograft Tumor Growth. American Journal of Pathology, 2013, 183, 257-265.	3.8	37
44	FOXM1: The Achilles' heel of cancer?. Nature Reviews Cancer, 2008, 8, 242-242.	28.4	35
45	Proteasome inhibitory activity of thiazole antibiotics. Cancer Biology and Therapy, 2011, 11, 43-47.	3.4	34
46	New potential antiâ€cancer agents synergize with bortezomib and ABTâ€737 against prostate cancer. Prostate, 2010, 70, 825-833.	2.3	33
47	FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy. Cell Cycle, 2011, 10, 3269-3273.	2.6	31
48	Thiazole antibiotics against breast cancer. Cell Cycle, 2010, 9, 1214-1217.	2.6	29
49	A Novel Function of Molecular Chaperone HSP70. Journal of Biological Chemistry, 2016, 291, 142-148.	3.4	28
50	Thiazole Antibiotic Thiostrepton Synergize with Bortezomib to Induce Apoptosis in Cancer Cells. PLoS ONE, 2011, 6, e17110.	2.5	28
51	Thiazole Antibiotics Siomycin a and Thiostrepton Inhibit the Transcriptional Activity of FOXM1. Frontiers in Oncology, 2013, 3, 150.	2.8	25
52	Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells. Cell Death and Disease, 2021, 12, 704.	6.3	19
53	The PPAR-? Agonist Pioglitazone Post-Trancriptionally Induces p21 in PC3 Prostate Cancer but Not in Other Cell Lines. Cell Cycle, 2005, 4, 575-577.	2.6	18
54	ARC Synergizes with ABT-737 to Induce Apoptosis in Human Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 1688-1696.	4.1	18

#	Article	IF	Citations
55	FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight, 2018, 3, .	5.0	18
56	A new mode of transcriptional repression by c-myc: methylation. Oncogene, 2006, 25, 1989-1990.	5.9	17
57	Proteasome inhibitors suppress the protein expression of mutant p53. Cell Cycle, 2014, 13, 3202-3206.	2.6	17
58	A novel p21WAF1/CIP1 transcript is highly dependent on p53 for its basal expression in mouse tissues. Oncogene, 2004, 23, 8154-8157.	5.9	15
59	p21WAF1/CIP1 may be a tumor suppressor after all. Cancer Biology and Therapy, 2007, 6, 1182-1183.	3.4	15
60	The oncogenic transcription factor FOXM1 and anticancer therapy. Cell Cycle, 2012, 11, 3341-3342.	2.6	15
61	FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML. Frontiers in Oncology, 2021, 11, 696532.	2.8	13
62	Transcriptional inhibitors, p53 and apoptosis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1786, 83-86.	7.4	12
63	Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton. Cancer Biology and Therapy, 2012, 13, 184-189.	3.4	12
64	Differential sensitivity of human colon cancer cell lines to the nucleoside analogs ARC and DRB. International Journal of Cancer, 2008, 122, 1426-1429.	5.1	11
65	Wild-type p53 protects normal cells against apoptosis induced by thiostrepton. Cell Cycle, 2009, 8, 2850-2851.	2.6	11
66	Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis. Cell Cycle, 2012, 11, 3370-3372.	2.6	10
67	Mechanisms of Apoptosis Induced by Anticancer Compounds in Melanoma Cells. Current Topics in Medicinal Chemistry, 2012, 12, 50-52.	2.1	9
68	Inducer and inhibitor: â€œAntagonistic dualityâ€•of p21 in differentiation. Leukemia Research, 2006, 30, 1215-1216.	0.8	8
69	Targeting FOXM1 auto-regulation in cancer. Cancer Biology and Therapy, 2015, 16, 185-186.	3.4	8
70	Therapeutic Vulnerabilities of Transcription Factors in AML. Molecular Cancer Therapeutics, 2021, 20, 229-237.	4.1	8
71	Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors. Scientifica, 2014, 2014, 1-5.	1.7	7
72	Proteasome inhibitors suppress expression of NPM and ARF proteins. Cell Cycle, 2011, 10, 3827-3829.	2.6	6

#	Article	IF	Citations
73	FOXM1 Binds Nucleophosmin in AML and Confers Resistance to Chemotherapy. Blood, 2015, 126, 2467-2467.	1.4	4
74	Identification of multiple B-cell transcriptional repressor elements in SÎ¼â^’CÎ¼ intron of mouse IgH chain locus. Somatic Cell and Molecular Genetics, 1994, 20, 371-379.	0.7	3
75	Found in transcription: FOXO1 upregulates miRNAs on chromosome X. Cell Cycle, 2013, 12, 2523-2523.	2.6	3
76	Mutual Regulation of FOXM1, NPM and ARF Proteins. Journal of Cancer, 2015, 6, 538-541.	2.5	3
77	A Novel P53-Related Activity in a Colon Adenocarcinoma Cell Line With Mutant P53. Scientific World Journal, The, 2001, 1, 36-36.	2.1	1
78	Paradoxical inhibition of cellular protein expression by proteasome inhibitors. Biomolecular Concepts, 2012, 3, 593-595.	2.2	1
79	Inhibition of FOXM1 By Ixazomib Confers Chemosensitivity in NPM1-Wild Type Acute Myeloid Leukemia. Blood, 2016, 128, 1577-1577.	1.4	0
80	The antagonistic duality of NPM1 mutations in AML. Blood Advances, 2022, , .	5.2	0